Literature DB >> 9122735

The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma.

R Essner1.   

Abstract

The presence or absence of regional nodal metastases is one of the most important prognostic factors for the survival of patients with primary cutaneous melanoma. The successful outcome of treatment is thus critically dependent on accurate staging of the primary tumor and detection of any occult micrometastases in the regional lymph nodes draining that tumor. Preoperative cutaneous lymphoscintigraphy to identify and visualize the lymphatic drainage patterns from primary tumors and intraoperative lymphatic mapping to identify the first ("sentinel") lymph node in direct communication with the primary tumor are valuable diagnostic tools. These techniques have greatly enhanced the oncologist's ability to identify occult lymph node metastases and to select patients with cutaneous melanoma who may potentially benefit from adjuvant therapy with recombinant interferon alpha-2b.

Entities:  

Mesh:

Year:  1997        PMID: 9122735

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

Review 1.  Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Authors:  Sanjay P Bagaria; Mark B Faries; Donald L Morton
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.